On ECHEMI
Home > Drugs > Acute myocardial infarction
Acute myocardial infarction
Acute myocardial infarction (AMI) refers to acute necrosis of part of the myocardium due to persistent and severe myocardial ischemia. Clinically, it is often manifested as chest pain, acute circulatory dysfunction, and a series of characteristic electrocardiogram changes reflecting myocardial damage, ischemia, and necrosis. Clinical manifestations often include persistent severe pain behind the sternum, acute circulatory dysfunction, arrhythmia, heart failure, fever, elevated white blood cell count and serum myocardial injury marker enzymes, and progressive electrocardiogram changes of acute myocardial damage and necrosis. According to the scope of infarction, myocardial infarction can be divided into two categories: transmural myocardial infarction and subendocardial myocardial infarction. According to the development process of the lesion, myocardial infarction can be divided into acute myocardial infarction and old myocardial infarction.
  • Site of disease:

    Heart blood vessels
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Chest pain cardiopulmonary embolism extensive myocardial necrosis upper abdominal pain chest tightness and breathlessness
  • Concurrent disease:

Related Drugs
Sodium fructose diphosphate
Indication: It is suitable for improving angina pectoris, acute myocardial infarction and arrhythmia caused by coronary heart disease, and myocardial ischemia caused by heart failure.
Manufacturer:

Shanghai SPH New ASIA Pharmaceutical Co., Ltd.

Sodium fructose diphosphate
Indication: It is suitable for improving angina pectoris, acute myocardial infarction and arrhythmia caused by coronary heart disease, and myocardial ischemia caused by heart failure.
Manufacturer:

Shanghai SPH New ASIA Pharmaceutical Co., Ltd.

Sodium fructose diphosphate
Indication: It is suitable for improving angina pectoris, acute myocardial infarction and arrhythmia caused by coronary heart disease, and myocardial ischemia caused by heart failure.
Manufacturer:

Shanghai SPH New ASIA Pharmaceutical Co., Ltd.

Lidocaine Hydrochloride Injection
Indication: This product is a local anesthetic and antiarrhythmic drug. It is mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block. This product can also be used for ventricular premature beats and ventricular tachycardia after acute myocardial infarction, and can also be used for ventricular arrhythmias caused by digitalis poisoning, cardiac surgery and cardiac catheterization. This product is usually ineffective for supraventricular arrhythmias.
Manufacturer:

Suicheng Pharmaceutical Co., Ltd.

Lidocaine Hydrochloride Injection
Indication: This product is a local anesthetic and antiarrhythmic drug. It is mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block. This product can also be used for ventricular premature beats and ventricular tachycardia after acute myocardial infarction, and can also be used for ventricular arrhythmias caused by digitalis poisoning, cardiac surgery and cardiac catheterization. This product is usually ineffective for supraventricular arrhythmias.
Manufacturer:

Zhengzhou Zhuofeng Pharmaceutical Co., Ltd.

Lidocaine Hydrochloride Injection
Indication: This product is a local anesthetic and antiarrhythmic drug. It is mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block. This product can also be used for ventricular premature beats and ventricular tachycardia after acute myocardial infarction, and can also be used for ventricular arrhythmias caused by digitalis poisoning, cardiac surgery and cardiac catheterization. This product is usually ineffective for supraventricular arrhythmias.
Manufacturer:

Shanxi JINXIN DOUBLE-CRANE Pharmaceutical Co., Ltd.

Metoprolol Tartrate Injection
Indication: Supraventricular tachyarrhythmias. Prevention and treatment of myocardial ischemia, suspected or confirmed acute myocardial infarction with tachyarrhythmias and chest pain.
Manufacturer:

Jiangsu Langou Pharmaceutical Co., Ltd.

Metoprolol Tartrate Injection
Indication: Supraventricular tachyarrhythmias. Prevention and treatment of myocardial ischemia, suspected or confirmed acute myocardial infarction with tachyarrhythmias and chest pain.
Metoprolol Tartrate Injection
Indication: Supraventricular tachyarrhythmias. Prevention and treatment of myocardial ischemia, suspected or confirmed acute myocardial infarction with tachyarrhythmias and chest pain.
Manufacturer:

Shandong FANGMING Pharmaceutical Group Co., Ltd.

Metoprolol Tartrate Injection
Indication: Supraventricular tachyarrhythmias. Prevention and treatment of myocardial ischemia, suspected or confirmed acute myocardial infarction with tachyarrhythmias and chest pain.
Manufacturer:

CSPC OUYI Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.